An update on the use of tolvaptan for autosomal dominant polycystic kidney disease : Consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International
Müller, Roman-Ulrich U. (Cecad. University of Cologne. Faculty of Medicine and University Hospital Cologne)
Messchendorp, A. Lianne (Department of Nephrology. University Medical Center Groningen. University of Groningen)
Birn, Henrik (Departments of Clinical Medicine and Biomedicine. Aarhus University)
Capasso, Giovambattista (Biogem Institute for Molecular Biology and Genetics)
Cornec-Le Gall, Emilie (University Brest. Inserm. Umr 1078. GGB. Chu Brest)
Devuyst, Olivier (Division of Nephrology. Ucl Medical School)
Van Eerde, Albertien (Department of Genetics. University Medical Center Utrecht)
Guirchoun, Patrick (Association PolyKystose France (PKD France))
Harris, Tess (Pkd International)
Hoorn, Ewout J. (University Medical Center Rotterdam)
Knoers, Nine V.A.M. (Department Genetics. University Medical Centre Groningen)
Korst, Uwe (Pkd Familiäre Zystennieren E.V.)
Mekahli, Djalila (Department of Pediatric Nephrology and Organ Transplantation. University Hospitals Leuven)
Le Meur, Yannick (Department of Nephrology. Hemodialysis and Renal Transplantation. Chu and University of Brest)
Nijenhuis, Tom (Radboud University Medical Center)
Ong, Albert C.M. (Sheffield Kidney Institute. Sheffield Teaching Hospitals Nhs Foundation Trust)
Sayer, John A. (Translational and Clinical Research Institute. Faculty of Medical Sciences. Newcastle University)
Schaefer, Franz (Division of Pediatric Nephrology. Center for Pediatrics and Adolescent Medicine. Heidelberg University Hospital)
Servais, Aaude (Nephrology and Transplantation Department. Necker University Hospital. Aphp)
Tesar, Vladimir (Department of Nephrology. 1st Faculty of Medicine. General University Hospital)
Torra Balcells, Roser (Institut d'Investigació Biomèdica Sant Pau)
Walsh, Stephen B. (Department of Renal Medicine. University College London)
Gansevoort, Roon T. (Department of Nephrology. University Medical Center Groningen. University of Groningen)
Universitat Autònoma de Barcelona

Data:	2022
Resum:	Approval of the vasopressin V2 receptor antagonist tolvaptan-based on the landmark TEMPO 3:4 trial-marked a transformation in the management of autosomal dominant polycystic kidney disease (ADPKD). This development has advanced patient care in ADPKD from general measures to prevent progression of chronic kidney disease to targeting disease-specific mechanisms. However, considering the long-Term nature of this treatment, as well as potential side effects, evidence-based approaches to initiate treatment only in patients with rapidly progressing disease are crucial. In 2016, the position statement issued by the European Renal Association (ERA) was the first society-based recommendation on the use of tolvaptan and has served as a widely used decision-making tool for nephrologists. Since then, considerable practical experience regarding the use of tolvaptan in ADPKD has accumulated. More importantly, additional data from REPRISE, a second randomized clinical trial (RCT) examining the use of tolvaptan in later-stage disease, have added important evidence to the field, as have post hoc studies of these RCTs. To incorporate this new knowledge, we provide an updated algorithm to guide patient selection for treatment with tolvaptan and add practical advice for its use.
Nota:	Altres ajuts: European Union within the framework of the Third Health Programme (ERN-2016-Framework Partnership Agreement 2017-2021); German Research Foundation; PKD Foundation.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	ADPKD ; Polycystic kidney disease ; Position statement ; Tolvaptan ; Vasopressin V2 receptor antagonist
Publicat a:	Nephrology Dialysis Transplantation, Vol. 37 Núm. 5 (january 2022) , p. 825-839, ISSN 1460-2385

DOI: 10.1093/ndt/gfab312
PMID: 35134221

15 p, 949.7 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats